NervGen Pharma Corp. Common stock (NGEN)
Stock · NASDAQ · Health Care
$1.59as of 10/16/2026
Price chart
Active signals
NGEN Signal Track Record
How signals performed across all stocks →What NGEN's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 48 | +1.2% | 52% | October 1, 2026 |
| Bollinger Band Breakout | 26 | -5.4% | 35% | August 21, 2026 |
| 200-Day Moving Average TouchActive now | 23 | -0.6% | 48% | May 18, 2026 |
| Bollinger Band Breakdown | 21 | +4.1% | 62% | September 23, 2026 |
| Any 20-session window (baseline) | -0.3% | 48% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About NGEN
NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer's disease; and NVG-300…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 9
- Website
- www.nervgen.com/
Fundamentals
- 1-day range
- $1.55$1.65
- Market cap
- $141.37M
- P/E (trailing)
- —
- P/E (forward)
- -4.78
- EPS (trailing)
- $-0.36
- Dividend yield
- —
- Beta
- 1.45
- Avg. volume
- 514.8K
Forecasts
1 analyst ratings
NervGen Pharma Corp. Common stock Competitors
Chosen by industry and closest market cap.
- NGENNervGen Pharma Corp. Common stock$1.59▼ 1.85%Market cap $141.37MP/E —$3.2$8.49
- KZIAKazia Therapeutics Limited American Depositary Shares$7.25▼ 2.03%Market cap $140.89MP/E —$4.86$17.4
- OGIOrganigram Global Inc. Common Shares$0.927▼ 0.54%Market cap $139.37MP/E 2.08$1.2$3.09
- CNTNCanton Strategic Holdings Inc. Common Stock$1.7▼ 9.36%Market cap $143.45MP/E —$1.75$6.89
- ADCTADC Therapeutics SA Common Shares$1.4▼ 6.04%Market cap $143.73MP/E —$0.7796$4.98
- UNCYUnicycive Therapeutics Inc. Common Stock$3.36▼ 6.41%Market cap $138.33MP/E —$3.56$8.74
- CNTBConnect Biopharma Holdings Limited Ordinary Shares$0.906▲ 0.00%Market cap $137.89MP/E —$0.8501$3.82
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| NGEN NervGen Pharma Corp. Common stock | $141.37M | — | $1.59 | ▼ 1.85% | $3.2$8.49 |
| KZIA Kazia Therapeutics Limited American Depositary Shares | $140.89M | — | $7.25 | ▼ 2.03% | $4.86$17.4 |
| OGI Organigram Global Inc. Common Shares | $139.37M | 2.08 | $0.927 | ▼ 0.54% | $1.2$3.09 |
| CNTN Canton Strategic Holdings Inc. Common Stock | $143.45M | — | $1.7 | ▼ 9.36% | $1.75$6.89 |
| ADCT ADC Therapeutics SA Common Shares | $143.73M | — | $1.4 | ▼ 6.04% | $0.7796$4.98 |
| UNCY Unicycive Therapeutics Inc. Common Stock | $138.33M | — | $3.36 | ▼ 6.41% | $3.56$8.74 |
| CNTB Connect Biopharma Holdings Limited Ordinary Shares | $137.89M | — | $0.906 | ▲ 0.00% | $0.8501$3.82 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- NervGen Doses First Participant In Phase 3 RESTORE Study Of NVG-291 For Chronic Cervical SCI; Enrollment Completion Expected In H2 2027, Topline Data In H1 2028benzinga · 10/12/2026
- NervGen Pharma: The Upside Is Large, But Phase 3 Decides EverythingSeekingAlpha · 10/1/2026
- NervGen Pharma Corp. (NGEN) Discusses Challenges and Advances in Drug and Therapy Trials for Spinal Cord Injury TranscriptSeekingAlpha · 9/30/2026
- NervGen to Restate Previously Filed Financial Statements Recognizing Non-Cash Accounting AdjustmentsYahoo · 9/25/2026
- NervGen Announces It Will Restate Its Audited Annual Financial Statements For The Year Ended December 31, 2025, And Its Unaudited Interim Financial Statements For The Quarter Ended June 30, 2026Benzinga · 9/25/2026
Institutional Ownership
March 31, 2026
- Total shares held
- 1.67M
- Total value held
- $6.17M
- Institutional holders
- 43
- Unknown201.0K
- Unknown200.7K
- Unknown200.4K
- Unknown172.0K
- Unknown86.8K
- Unknown77.7K
- Unknown62.9K
- Unknown62.4K
- Unknown61.5K
- Unknown40.0K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
NervGen to restate 2025 annual and Q2 2026 financials
NervGen announced it will restate its audited 2025 annual financial statements and unaudited interim statements for the quarter ended June 30, 2026. The company stated these restatements involve non-cash accounting adjustments. This disclosure is significant for investors as it requires a formal correction of previously reported financial data.
NervGen to restate 2025 annual and Q2 2026 financials. NervGen announced it will restate its audited 2025 annual financial statements and unaudited interim statements for the quarter ended June 30, 2026. The company stated these restatements involve non-cash accounting adjustments. This disclosure is significant for investors as it requires a formal correction of previously reported financial data.